iCAD (NASDAQ:ICAD) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research note published on Wednesday.

iCAD Price Performance

Shares of ICAD stock opened at $2.14 on Wednesday. The business has a 50-day moving average price of $2.68 and a two-hundred day moving average price of $2.08. iCAD has a 12-month low of $1.18 and a 12-month high of $3.78. The firm has a market cap of $56.80 million, a P/E ratio of -16.46 and a beta of 1.95.

iCAD (NASDAQ:ICAD) last released its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The company had revenue of $5.41 million during the quarter, compared to the consensus estimate of $4.72 million.

Institutional Trading of iCAD

Institutional investors have recently modified their holdings of the company. waypoint wealth counsel raised its holdings in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after acquiring an additional 4,400 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in iCAD in the 4th quarter worth $31,000. PKS Advisory Services LLC purchased a new stake in shares of iCAD in the 4th quarter worth about $53,000. Wells Fargo & Company MN boosted its stake in shares of iCAD by 51.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after purchasing an additional 13,402 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of iCAD during the fourth quarter valued at about $92,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.